Research

Hormonal

Semaglutide is associated with a statistically significant signal of disproportionate reporting for depressive disorders in real-world pharmacovigilance data, whereas liraglutide and tirzepatide show no such signal.

If you are taking semaglutide, be aware that real-world data shows a higher reporting rate of depression compared to other GLP-1RAs like liraglutide or tirzepatide. This does not mean the drug definitely causes depression, but it suggests you should monitor your mood, especially if you are female. Discuss any mood changes with your doctor, as they may consider drug-specific monitoring.

ModerateSupportsMEDIUM confidence
Only semaglutide demonstrated statistically significant SDRs for depressive disorders in both databases (FAERS: ROR 1.26... VigiBase: ROR 1.38...), while liraglutide and tirzepatide showed no SDRs.
Min Wang et al. · EClinicalMedicine · 2025

Why this rating

Pharmacovigilance signals indicate association but do not prove causality; the paper notes insufficient evidence for causal inference.

Source

Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data

Min Wang et al. · EClinicalMedicine · 2025

DOI 10.1016/j.eclinm.2025.103385

cohortCited 15×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →